In clinical trials, Mounjaros active ingredient, tirzepatide, helped people lose 22.5% on average, while semaglutide (Ozempic and Wegovys active ingredient) helped people lose around 21% of their starting weight
There is increasing recognition of the impact of obesity on workforce health (and as a result, on GDP), which further strengthens the case for healthcare systems investing more to enable additional widespread uptake of GLP-1RAs
Today, semaglutide is prescribed by physicians worldwide as one of the most effective non-surgical tools for significant, sustained weight loss
The Relationship between Methylation and Glutathione Methylation is necessary for the synthesis of glutathione
The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain